Payment overview · 2025
General Payments
$172.67
10 reported records · 6 companies
Healthcare provider profile · identity verified
Robert Austin Daro, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DAVID CITY, NE · NPI 1922368935
Verified facts
What the public records show
CMS Open Payments records show Robert Austin Daro, M.D. received $172.67 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 31.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.10 | 31.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.65 | 23.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.24 | 19.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.98 | 9.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.79 | 8.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.91 | 8.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $172.67 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $39.12 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.24 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.24 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 125 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
125 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
209 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 557 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 479 | 96 |
| Furosemide | Furosemide | 385 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 365 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 279 | 39 |
| Omeprazole | Omeprazole | 241 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 37 |
| Lisinopril | Lisinopril | 237 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 43 |
| Eliquis | Apixaban | 209 | 31 |
| Sertraline Hcl | Sertraline Hcl | 193 | 23 |
| Prednisone | Prednisone | 165 | 82 |
| Gabapentin | Gabapentin | 155 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 24 |
| Metformin Hcl | Metformin Hcl | 145 | 40 |
| Warfarin Sodium | Warfarin Sodium | 145 | 19 |
| Memantine Hcl | Memantine Hcl | 139 | 11 |
| Donepezil Hcl | Donepezil Hcl | 138 | 15 |
| Losartan Potassium | Losartan Potassium | 132 | 28 |
| Trazodone Hcl | Trazodone Hcl | 126 | 14 |
| Jardiance | Empagliflozin | 125 | 11 |
| Potassium Chloride | Potassium Chloride | 121 | 20 |
| Xarelto | Rivaroxaban | 116 | 12 |
| Tramadol Hcl | Tramadol Hcl | 113 | 21 |
| Meloxicam | Meloxicam | 110 | 22 |
| Lorazepam | Lorazepam | 109 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 27 |
| Allopurinol | Allopurinol | 105 | 24 |
| Carvedilol | Carvedilol | 105 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 23 |
| Myrbetriq | Mirabegron | 98 | suppressed |
| Alprazolam | Alprazolam | 89 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 88 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 14 |
| Alendronate Sodium | Alendronate Sodium | 65 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 15 |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Loperamide | Loperamide Hcl | 53 | suppressed |
| Baclofen | Baclofen | 52 | suppressed |
| Finasteride | Finasteride | 49 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 47 | suppressed |
| Amoxicillin | Amoxicillin | 46 | 16 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 11 |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Azithromycin | Azithromycin | 43 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 40 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 39 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 16 |
| Simvastatin | Simvastatin | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 33 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Budesonide Ec | Budesonide | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 26 | suppressed |
| Amantadine | Amantadine Hcl | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Rytary | Carbidopa/Levodopa | 23 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 14 |
| Atenolol | Atenolol | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Lorazepam Intensol | Lorazepam | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $172.67 · 10 records | Lilly USA, LLC | AIRSUPRA, EVENITY, FARXIGA, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, PROLIA, REXULTI, Rybelsus, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error